Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 61NIH 18INDUSTRY 15NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Sarcoma, Alveolar Soft Part 1Carcinoma, Renal Cell 1

Interventions

Specimen Handling 38Magnetic Resonance Spectroscopy 33Biopsy 16Radiation 15Cyclophosphamide 15Radiotherapy 14Vincristine 12Leucovorin 11Dexamethasone 11Carboplatin 11Etoposide 10Cisplatin 10Cytarabine 9Calcium Dobesilate 9dexamethasone acetate 8dexamethasone 21-phosphate 8auricularum 8Fluorouracil 8X-Rays 7Standard of Care 7Radiotherapy, Intensity-Modulated 7Practice Guidelines as Topic 7Platinum 7Doxorubicin 71,2-diaminocyclohexaneplatinum II citrate 7merphos 6dehydroftorafur 6Taxes 6Methotrexate 6Irinotecan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × fludarabine × 30 days × Clear all
NCT07297667 2026-05-12

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

Canadian Cancer Trials Group

Phase 1 Not yet recruiting
30 enrolled
BreastGenitourinarySarcoma

Carcinoma, Renal Cell, Sarcoma, Alveolar Soft Part, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡